What Revivicor does

Revivicor is a biotechnology company and wholly-owned subsidiary of United Therapeutics Corporation (NASDAQ: UTHR), specializing in xenotransplantation through the development of genetically engineered pig organs for transplantation into human recipients. The company's core technical platforms include gene-edited pig kidneys (xenokidneys) with up to ten genetic modifications designed to reduce immune rejection, as well as the xenothymokidney, a novel construct that combines a pig kidney with thymic tissue intended to induce immune tolerance. Revivicor also maintains pathogen-free donor pig herds that supply organs meeting safety requirements for human transplantation.

Revivicor's commercial activity is currently structured around clinical trials, compassionate use authorizations, and research collaborations with leading transplant centers, most notably NYU Langone Health and Mayo Clinic Jacksonville. The company achieved several landmark firsts in 2024, including the first living-patient transplant of a gene-edited pig kidney (Towana Looney, November 2024, with 130 days of organ function) and the first successful transplants of the xenothymokidney and ten-gene-edit xenokidney constructs. Revenue is not separately disclosed; operations are funded and consolidated within United Therapeutics, whose broader organ manufacturing ecosystem (Lung Bioengineering, Miromatrix Medical, IVIVA Medical, Thymmune Therapeutics, Unither Bioelectronics) provides manufacturing, delivery, and complementary regenerative medicine capabilities.

The company is led by co-founder David Ayares, who serves as Chief Executive Officer and Chief Scientific Officer. As a clinical-stage subsidiary rather than a standalone commercial entity, Revivicor's go-to-market is effectively B2B supply of organs and licensing of xenotransplantation technology to research institutions and transplant centers, with distribution limited to the United States and pricing not publicly disclosed.

Name

Revivicor

Legal name

Revivicor Inc.

Website

https://revivicor.com

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

11–50 employees

Short description

Revivicor is a United Therapeutics subsidiary that develops genetically engineered pig kidneys, including ten-gene-edit xenokidneys and xenothymokidneys, for human xenotransplantation. It supplies transplant centers and research institutions conducting clinical trials and compassionate use procedures in the United States.

Ownership category

akta.pro rank

Headquarters

HQ city

Blacksburg

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Supply Chain

Revenue model

1. Xenotransplantation Organs and Technology Licensing: Revivicor generates revenue through supplying genetically engineered pig organs for transplantation research and clinical trials, and through licensing its xenotransplantation technology. As a subsidiary of United Therapeutics, it supports the parent company's organ manufacturing and transplant expansion mission.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Revivicor develops and supplies genetically engineered pig kidneys (xenokidneys), including a ten-gene-edit variant and a novel porcine xenothymokidney, for use in clinical xenotransplantation. Its organs are produced from designated pathogen-free herds and supplied to transplant centers and research institutions conducting FDA-authorized clinical trials and compassionate-use transplants to address the human donor organ shortage.

Product overview

Revivicor is a biotechnology company and subsidiary of United Therapeutics focused on xenotransplantation - developing genetically engineered pig organs for human transplantation. The company's core products are gene-edited pig kidneys (xenokidneys) that have been modified to reduce immune rejection when transplanted into humans. Revivicor has pioneered several breakthroughs including the first successful transplant of a porcine xenothymokidney and ten-gene-edited xenokidneys, positioning itself at the forefront of addressing the global organ donor shortage through xenotransplantation technology.

Differentiator

Problem solved

Functional benefit

Products and services

• Gene-Edited Pig Kidneys (Xenokidneys) Genetically engineered pig kidneys with multiple gene edits designed to reduce immune rejection in human recipients; supplied to transplant centers and research institutions for xenotransplantation clinical trials and compassionate-use procedures.
• Porcine Xenothymokidney A novel combination product pairing a gene-edited pig kidney with thymic tissue, intended to promote immune tolerance and reduce rejection in human transplant recipients.
• Gene-Edited Pig Kidney Xenotransplant (Living Patient) Clinical-grade Revivicor gene-edited pig kidney supplied for transplantation into a living human patient under FDA compassionate-use authorization.

Quantifiable outcome

• First successful living patient xenotransplantation with 130-day organ function
• +2 more outcomes

Named customers4 records

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Eleven partnerships are on record, tiered technology partner, core, subsidiary and strategic.

• MannKindtechnology partnerTechnology or Integration · 1 January 2017United Therapeutics launched collaboration with MannKind for development and commercialization of Tyvaso DPI (treprostinil inhalation powder) using MannKind's Technosphere technology.
• Mayo Clinic JacksonvillecoreStrategic or Co-development Partner · 1 January 2015United Therapeutics constructed the Discovery and Innovation Center in Jacksonville, Florida as part of collaboration with Mayo Clinic Jacksonville. The facility houses a net-zero laboratory for ex vivo lung perfusion and Mayo's Innovation Exchange, a life sciences incubator.
• National Cancer InstitutecoreStrategic or Co-development Partner · 1 January 2010United Therapeutics launched collaboration with National Cancer Institute to develop monoclonal antibody for treatment of high-risk neuroblastoma, which became Unituxin (dinutuximab).
• IVIVA MedicalsubsidiaryStrategic or Co-development PartnerIVIVA Medical is a subsidiary of United Therapeutics developing preclinical kidney products that integrate patient-derived cells and novel biomimetic scaffolds using 3D printing technology. Their proprietary scaffold construction technology builds hollow vascular networks layered to create composite matrices at human scale. Products may not require immunosuppression.
• Lung BioengineeringsubsidiaryStrategic or Co-development PartnerLung Bioengineering is a United Therapeutics subsidiary providing centralized ex vivo lung perfusion (EVLP) services designed to increase the pool of available donor lungs for transplantation. LBE has performed over 500 lung transplants using its EVLP service.
• Miromatrix MedicalsubsidiaryStrategic or Co-development PartnerMiromatrix develops bioengineered human organs using proprietary perfusion decellularization and recellularization technology that harnesses evolutionary forces shaping complex organ development and regenerative capabilities of living human cells. Acquired by United Therapeutics in 2023.
• Thymmune TherapeuticssubsidiaryStrategic or Co-development PartnerThymmune has a proprietary process for converting human-induced pluripotent stem cells (iPSC) into thymic cells, which mature into cell types that can restore healthy T-cell function. Technology could resolve root causes of life-threatening diseases by restoring T-cell receptor diversity.
• Unither BioelectronicssubsidiaryStrategic or Co-development PartnerUnither Bioelectronics is focused on designing an efficient and environmentally-friendly transportation system, including a fleet of autonomous aircraft, capable of delivering organs from manufacturing facilities to transplant centers within a single day.
• NYU Langone HealthcoreStrategic or Co-development PartnerNYU Langone Health conducted research using Revivicor-provided pig kidneys, performing a 61-day study transplanting genetically modified pig kidney into a brain-dead recipient. The study created a detailed immune activity map and identified three distinct rejection phases.
• 3D SystemsstrategicStrategic or Co-development PartnerUnited Therapeutics' subsidiary Lung Biotechnology PBC launched an organ bioprinting program in collaboration with 3D Systems for developing manufactured organs.
• DEKA Research & Development Corp.technology partnerTechnology or IntegrationUnited Therapeutics entered agreement with DEKA Research to develop next-generation subcutaneous pump for Remodulin, resulting in the Remunity Pump for Remodulin.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• eGenesis: eGenesis develops gene-edited pig organs (kidneys, hearts, livers) for xenotransplantation using CRISPR-based multi-gene edits — directly competing with Revivicor in the same gene-edited pig kidney transplant market.
• IVIVA Medical: IVIVA Medical is a UTHR subsidiary developing preclinical kidney products using patient-derived cells and 3D-printed biomimetic scaffolds; comparable as another UTHR-affiliated kidney-focused transplant platform directly addressing end-stage renal disease.
• Miromatrix Medical: Miromatrix (acquired by United Therapeutics in 2023) develops bioengineered human organs via perfusion decellularization/recellularization; a sister UTHR subsidiary pursuing an alternative decellularized-organ path to the same transplant market.
• Thymmune Therapeutics: Thymmune is a UTHR subsidiary developing iPSC-derived thymic cells to restore T-cell function; directly comparable to Revivicor's xenothymokidney concept, since both programs use thymic tissue to drive immune tolerance in transplant recipients.

Broad incumbents

• Lung Bioengineering: Lung Bioengineering is a UTHR subsidiary providing centralized ex vivo lung perfusion (EVLP) services and has enabled over 500 lung transplants; comparable as a sister transplant-infrastructure platform leveraging the same UTHR distribution and regulatory backbone.
• United Therapeutics Corporation: Revivicor's publicly-traded parent (NASDAQ: UTHR) is a rare-disease pharmaceutical and organ-manufacturing company; comparable as the broader incumbent that funds, regulates, and commercializes Revivicor's pipeline.
• TransMedics: TransMedics is a publicly-traded organ transport and preservation system provider (Organ Care System); comparable as a transplant-enablement incumbent addressing the same donor-organ logistics and utilization gap that Revivicor's xenografts aim to bypass.

Emerging players

• OrganOx: OrganOx develops ex vivo organ perfusion and preservation technology for livers and kidneys; comparable as an enabling platform in the transplant supply chain that complements or competes with UTHR's EVLP-based organ expansion strategy.
• eGenesis Bio / Makana Therapeutics (predecessor): Makana Therapeutics was the predecessor xenotransplantation entity that merged with eGenesis; relevant as a historic comparability point illustrating how competing gene-edited pig platforms have consolidated in the xenotransplantation field.

Others

• 3D Systems (Healthcare / Regenerative Medicine): 3D Systems partnered with United Therapeutics (Lung Biotechnology PBC) on bioprinted organs; comparable as an enabling technology partner in the manufactured-organ space adjacent to Revivicor's gene-edited xenograft pipeline.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/revivicor-inc.

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Revivicor